Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Near-Infrared Fluorescence Molecular Imaging of ANXV-800CW in RVO
NCT05133791Phase 1Unknown
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2021
- Primary completion
- Jan 2024
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of ANXV-800CW in retinal vein occlusion (RVO) (3 cohorts), sponsored by University Medical Center Groningen. Primary endpoints: Safety of near-infrared fluorescent imaging at 1.5 years, Tolerability of near-infrared fluorescent imaging at 1.5 years and 1 more. Status: unknown.
02
Drugs
ANXV-800CW
03
Conditions
retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT05133791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05133791.